Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6783870 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2MEN1KMT2ALMNAKDM4E | |
| SCHEMBL7647664 | 0.80 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2ALMNAKDM4E | |
| SCHEMBL6783536 | 0.80 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2ALMNAKDM4E | |
| SCHEMBL12550714 | 0.80 | RXRA (0.53) | SMN1; SMN2HPGDMEN1KMT2ANLRP3 | |
| SCHEMBL12086822 | 0.74 | CTDSP1 (0.54) | MAPK1HPGDMEN1KMT2ALMNA | |
| SCHEMBL16664723 | 0.74 | CYP11B1 (0.34) | SMN1; SMN2MAPK1HPGDHSD17B10MEN1 | |
| SCHEMBL13604505 | 0.74 | CTDSP1 (0.54) | MAPK1HPGDMEN1KMT2ALMNA | |
| SCHEMBL16664724 | 0.74 | CYP11B1 (0.34) | SMN1; SMN2MAPK1HPGDHSD17B10MEN1 | |
| SCHEMBL13441754 | 0.74 | CTDSP1 (0.54) | MAPK1HPGDMEN1KMT2ALMNA | |
| SCHEMBL7395455 | 0.73 | RXRA (0.49) | SMN1; SMN2HPGDHSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727250-B2 | ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-04-27 | — | — | US | disclosed |
| US-20020099089-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-07-25 | — | — | US | disclosed |
| US-6362210-B1 | ANTITUMOR, ANTICANCER AGENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099089-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | TERT, NAT1, POT1 | SMN1; SMN2 62/4885MAPK1 599/4885HPGD 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.